Table 1.
Population characteristics.
| No PCI (N = 31) | PCI (N = 25) | p | |
|---|---|---|---|
| Age mean (min–max) | 64 (47–81) | 65 (47–87) | 0.656 |
| Smoking status | 0.580 | ||
| - Non-smoker | 1 (3.2%) | 0 | |
| - Former smoker | 23 (74.2%) | 15 (69.1%) | |
| - Current smoker | 7 (22.6%) | 9 (37.5%) | |
| Sex | 0.580 | ||
| - Men | 18 (58.1%) | 17 (68%) | |
| - Women | 13 (41.9%) | 8 (32%) | |
| Clinical tumor status | 0.450 | ||
| - T1 | 3(9.7%) | 0 | |
| - T2 | 6 (19.4%) | 4 (17.4%) | |
| - T3 | 13 (41.9%) | 9 (39.1%) | |
| - T4 | 9 (29%) | 10 (43.5%) | |
| Clinical node status | 0.112 | ||
| - N0 | 3 (9.7%) | 0 | |
| - N1 | 3 (9.7%) | 2 (8.3%) | |
| - N2 | 18 (58.1%) | 10 (41.7%) | |
| - N3 | 7 (22.6%) | 12 (50%) | |
| Clinical metastasis status | 0.688 | ||
| - M0 | 3 (9.7%) | 4 (16%) | |
| - M1 | 28 (90.3%) | 21 (84%) | |
| Stage | 0.606 | ||
| - Stage III | 3 (9.7%) | 4 (16%) | |
| - Stage IV | 28 (90.3%) | 21 (84%) | |
| Initial PS | 0.622 | ||
| - 0/1 | 25 (80.6%) | 21 (84%) | |
| - 2 | 6 (19.3%) | 4 (16%) | |
| Neurological history | 6 (19.4%) | 3 (33.3%) | 0.716 |
| Response befor PCI | 0.155 | ||
| - Stable | 0 | 2 (8%) | |
| - Partial response | 27 (87.1%) | 22 (88%) | |
| - Complete response | 4 (12.9%) | 1 (4%) | |
| Immunotherapy | 14 (45.2%) | 4 (16%) | 0.024 |
| Initial MRI | 15 (48.4%) | 12 (48%) | 0.977 |
| Diagnostic year (mean) | 2018 | 2015 | 0.000 |
| Monocyte to lymphocyte ratio MLR (mean) | 0.87 | 0.35 | 0.178 |
| Neutrophil to lymphocyte ratio NLR (mean) | 4.9 | 4.8 | 0.803 |